LOS ANGELES and TAMPA, Fla., April 1 /PRNewswire/ -- Stem Cell Biotherapy ("SCB") announced that it filed a lawsuit today in Los Angeles County Superior Court against the Company's Co-Founder and former President Casey Nabavi of Calabasas, California, for among other things conduct by Nabavi giving rise to patient claims against Nabavi that he had misrepresented himself as a medical doctor, practiced medicine without a license, supervised the injection of stem cells which caused some patients to become ill and personally advised patients how to manage these side effects. Nabavi/Cellulogix have offices/clinics in Los Angeles, Tampa, Montreal, Zona Rio (Mexico) and Istanbul.
The SCB lawsuit also seeks to recover SCB funds in excess of $1.65 million that Navabi paid himself before leaving SCB, to recover assets including intellectual property belonging to SCB which Navabi took and used to start-up the new Cellulogix business, to prevent Nabavi from continuing to compete with SCB in contravention of the parties' non-competition agreement and for SCB to recover ownership, the business and profits of Cellulogix as belonging to SCB not to Navabi as a result of Nabavi's wrongful conduct and activities. A copy of the SCB lawsuit against Nabavi and Cellulogix can be viewed at the Company's web site www.stemcellbiotherapy.com at "Recent News".
SCB is in the business of assisting persons who desire to try stem cell therapy treatment for serious medical problems which have not responded to traditional medical treatments. SCB uses medical clinics and specialized doctors in locations around the world where stem cell therapy is authorized to treat medical conditions such as spinal cord injury, ALS, Parkinsonism, Alzheimer's, multiple sclerosis, autism, cerebral palsy, brain damage, heart disease, COPD, kidney diseases, eye diseases, diabetes, transverse myelitis, etc. SCB also offers age rejuvenation programs for persons seeking to reverse the effects of aging.
The U.S. FDA recently announced that it was approving Geron Corporation to engage in a clinical trial with embryonic stem cells to treat spinal cord injuries; and the Obama Administration recently reversed the Bush Administration's prohibition against federal funding for embryonic stem cell research.
For Further Information, Contact Burton Feinerman, M.D. at SCB 1-888-620-0411 http://www.stemcellbiotherapy.com/
|SOURCE Stem Cell Biotherapy|
Copyright©2009 PR Newswire.
All rights reserved